Drawing for ONKO-INNATE

USPTO serial 79292390

ONKO-INNATE

Reviewed by CopyMark Law Group

Reg. 6617149Status 700Registered
Filing date
Status date
Registration date
Jan 18, 2022
Examiner
LINDEMYER, ANKHI MUKHERJEA
Law office
PUBLICATION AND ISSUE SECTION

What this means

Status 700 means the trademark is registered and active on the Principal Register. You have nationwide rights for the listed goods and services and may use ®. Section 8 maintenance is due between years five and six. Calendar Section 8 between years five and six, and consider trademark monitoring.

Status 700: Status 700 means the trademark is registered and active on the Principal Register. You have nationwide rights for the listed goods and services and may use ®. Section 8 maintenance is due between years five and six.

Need help with ONKO-INNATE?

If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.

Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.

Owner

Attorney of record

The USPTO lists this attorney as the applicant's representative for correspondence on this application.

Andrew S. Ehard

Andrew S. Ehard Merchant & Gould P.C.P.O. Box 2910dockmpls@merchantgould.comMinneapolis, MN 55402

Goods and services

ClassDescriptionStatusFirst use
005Pharmaceutical drugs for the treatment of cancer and immune cell related disorders; pharmaceutical preparations for the treatment of cancer and immune cell related disorders; stem cells for medical purposes; living cells for medical use; pharmaceutical and biological preparations for the treatment of cancer; biological preparations for medical use for the treatment of cancer and immune cell related disorders; chemicals for pharmaceutical use for the treatment of cancer and immune cell related disordersACTIVE—
042Scientific research; pharmaceutical research, development and testing services; scientific research, namely, preparation of scientific reports; advisory services relating to immunological product development and testing; scientific research, design, analysis and testing of pharmaceutical products; conducting scientific and medical research and clinical trials; scientific research in the field of immunology and cancer treatment; scientific research and testing in the field of natural killer cells; provision of scientific information in the field of immunology, cancer treatment and the treatment of immune cell related disorders; scientific and technical analysis, namely, scientific research, analysis and testing in the field of immunology, cancer treatment and the treatment of immune cell related disorders; scientific research consultancy in the field of immunology, cancer treatment and the treatment of immune cell related disorders; scientific research in the field of pharmacy; medical research; research and development of products; research relating to pharmaceuticalsACTIVE—

Related trademarks

CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.

Prosecution history

DateCodeEventWhat it means
Oct 8, 2026NREPNEW REPRESENTATIVE AT IB RECEIVED—
Sep 18, 2022ADCHCHANGE OF NAME/ADDRESS REC'D FROM IB—
Aug 14, 2022NREPNEW REPRESENTATIVE AT IB RECEIVED—
Jul 18, 2022FINOFINAL DECISION TRANSACTION PROCESSED BY IB—
Jun 28, 2022FICSFINAL DISPOSITION NOTICE SENT TO IB—
Jun 27, 2022FIMPFINAL DISPOSITION PROCESSED—
Apr 18, 2022FICRFINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB—
Jan 18, 2022R.PRREGISTERED-PRINCIPAL REGISTERYour trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive.
Dec 12, 2021ETOPEXTENSION OF TIME TO OPPOSE PROCESS - TERMINATED—
Nov 3, 2021DOCKASSIGNED TO EXAMINER—
Sep 1, 2021ETOFEXTENSION OF TIME TO OPPOSE RECEIVED—
Aug 3, 2021NPUBOFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED—
Aug 3, 2021PUBOPUBLISHED FOR OPPOSITIONYour mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance.
Aug 1, 2021GPNXNOTIFICATION PROCESSED BY IB—
Jul 14, 2021OPNSNOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB—
Jul 14, 2021OP2RNOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB—
Jul 14, 2021NONPNOTIFICATION OF NOTICE OF PUBLICATION E-MAILED—
Jun 28, 2021CNSAAPPROVED FOR PUB - PRINCIPAL REGISTER—
May 21, 2021TEMETEAS/EMAIL CORRESPONDENCE ENTERED—
May 20, 2021CRFACORRESPONDENCE RECEIVED IN LAW OFFICE—
May 20, 2021TROATEAS RESPONSE TO OFFICE ACTION RECEIVEDThis event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action.
Apr 6, 2021ATRVATTORNEY REVIEW COMPLETED—
Mar 24, 2021LIMELIMITATION FROM THE IB - REQUEST EXAM REVIEW—
Feb 13, 2021LIMGLIMITATION OF GOODS RECEIVED FROM IB—
Dec 20, 2020RFNTREFUSAL PROCESSED BY IB—
Dec 1, 2020RFCSNON-FINAL ACTION MAILED - REFUSAL SENT TO IB—
Dec 1, 2020RFRRREFUSAL PROCESSED BY MPU—
Nov 14, 2020RFCRNON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW—
Nov 13, 2020CNRTNON-FINAL ACTION WRITTENA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Nov 9, 2020DOCKASSIGNED TO EXAMINER—
Sep 1, 2020MAFRAPPLICATION FILING RECEIPT MAILED—
Aug 28, 2020NWOSNEW APPLICATION OFFICE SUPPLIED DATA ENTERED—
Aug 27, 2020REPRSN ASSIGNED FOR SECT 66A APPL FROM IB—

Frequently asked questions

Related guidance